Decipher is consistent across trials in IDing group benefiting from intensification. @ChrisSweens1 presents data from ENZAMET - great collab btw @Decipher_VCYT@ANZUPtrials and participating centers. More molecular data coming from ENZAMET - see our germline profiling poster tmrw
Personalized intensification of treatment for hormone-sensitive prostate cancer
https://t.co/S98ko2tEWm
Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology.
Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care.
@drcilento@LisaButler5@drlouiseemmett@ChrisSweens1@OncoAlert 🚨
@Silke_Gillessen@AOmlin@weoncologists
Personalized intensification of treatment for hormone-sensitive prostate cancer @NatRevClinOncol
Goal: hit cancer harder, earlier & smarter with biology, risk & PSMA-PET. ADT+ARPI = backbone for most pts.
Docetaxel for de novo high-volume.
Prostate RT: survival boost in low-volume.
Enzalutamide±ADT: best for high-risk BCR.
🌟PSMA-PET reshapes staging, EMBARK showed M1 in 46% despite negative CT/Bone scan (~30-40% higher detection)
Next discussions: integrating 177Lu-PSMA, AKT & PARP inhibitors after +ve trials with biomarkers as the key to pt selection ✅
Really nice review
https://t.co/1sAL8AcJRo @OncoAlert
The second #ProstateCancer session at #UromigosLive 2025 was a discussion about the approach to mHSPC, building on ADT+ARPI and debating the inclusion of a third agent including docetaxel, PARPi, radioligand or AKT inhibition. https://t.co/6Zy9duoviM for full videos with slides. @OncoAlert
Immune checkpoint inhibitors can improve survival in solid organ transplant recipients with advanced cancers, but survival rates remain limited.
#TSANZConf@TSANZ_txsoc
https://t.co/L80IACCN4e
Stunning research from @EdmondMKwan on ctDNA in theranostics:
🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy
⚠️PTEN alterations linked to worse outcomes on cabazitaxel
🧪ATM defects tied to favorable PSMA-617 results
🩻PET quantitative biomarkers (SUVmean) are additive
🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire
Online at @NatureMedicine
https://t.co/WvEQS4ZWol
@ANZUPtrials #TheraP @MovemberAUS@PCFA
Support by @PCF_Science Challenge Award
@ResearchWyatt@AzadOncology@Prof_IanD
Great to see a full-house for @SAiGENCI's third Annual Public Lecture on Tuesday night featuring @Lab_Jenkins and @marazeissig speaking on the topic of "Fighting cancer from within: your immune system may hold the key" https://t.co/cyM2wx9iOT @UniofAdelaide
Latest journey in #prostatecancer cell plasticity. Team effort @ChrisSweens1@kat_morel@BeatrizGerFalc
Work stems from previous @ChrisSweens1 investigations in NFkB regulation by tristetraprolin (TTP; gene ZFP36), and generation of the NFkBi dimethylaminoparthenolide (DMAPT)
🌟A huge thank you to our amazing speakers & everyone who joined us for our special Seminar on Wed to announce the Awardees of the SA #Multiomics Framework Initiative @BioplatformsAus & celebrate their groundbreaking projects! 👏 We can't wait to see the impact of your work! 🚀🔬
🌟Support SAiGENCI Cancer Research and help fund groundbreaking science! Plus, you can double your impact through matched giving on Giving Day! Let's make a lasting impact together. 💪🌍 #UoAGivingDay#UAMakeHistory Donate now!
https://t.co/YVwoLUGVkg